CNSY: Cerenome, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
22 institutions reported holding $2.77M of Cerenome, Inc. on Form 13F (1 the quarter before). 19 opened a new position and 0 sold out. Shares held by institutions: new.
| Largest holders | Shares | Value |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 304,745 | $1.33M |
| BlackRock, Inc. | 95,983 | $419K |
| GEODE CAPITAL MANAGEMENT, LLC | 76,155 | $333K |
| VANGUARD FIDUCIARY TRUST CO | 36,868 | $161K |
| Ashton Thomas Private Wealth, LLC | 34,306 | $150K |
| STATE STREET CORP | 30,853 | $135K |
| CITADEL ADVISORS LLC | 25,597 | $112K |
| NORTHERN TRUST CORP | 15,516 | $68K |
| WELLS FARGO & COMPANY/MN | 6,156 | $27K |
| Vanguard Global Advisers, LLC | 2,282 | $10K |
Clinical trial readouts
2 Phase 2 or 3 trials by Cerenome, Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-10-02 (est.) | 186RNL | Leptomeningeal Metastasis | Phase 1/2 | 24 | Recruiting | NCT07098806 |
| 2027-04 (est.) | Rhenium Liposome Treatment | Glioma | Phase 1/2 | 55 | Recruiting | NCT01906385 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.